Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.960
+0.110 (5.95%)
At close: Jul 21, 2025, 4:00 PM
1.980
+0.020 (1.02%)
Pre-market: Jul 22, 2025, 9:10 AM EDT
Neumora Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Neumora Therapeutics stock have a consensus rating of "Buy" and an average price target of $7.14, which forecasts a 264.29% increase in the stock price over the next year. The lowest target is $1 and the highest is $18.
Price Target: $7.14 (+264.29%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neumora Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +155.10% | Jul 16, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +155.10% | May 13, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +155.10% | Apr 10, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $1 | Strong Buy → Sell | Downgrades | $7 → $1 | -48.98% | Apr 2, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 265.69M
Revenue Next Year
n/a
EPS This Year
-1.44
from -1.53
EPS Next Year
-1.05
from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 26.3M | 42.0M | ||
| Avg | n/a | 5.1M | 10.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 723.5% | ||
| Avg | - | - | 98.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.90 | -0.38 | -0.26 | ||
| Avg | -1.44 | -1.05 | -1.02 | ||
| Low | -1.75 | -1.73 | -1.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.